Sep 06, 2023 / 03:00PM GMT
Mohit Bansal - Wells Fargo Securities, LLC, Research Division - Senior Equity Analyst
All right. Thank you very much for joining us today. My name is Mohit Bansal. I'm one of the biopharma analysts here at Wells Fargo. And we have Andy Dickinson, CFO of Gilead with us. I think this is fifth year in a row. I'm hosting you at different platforms...
Andrew D. Dickinson - Gilead Sciences, Inc. - Executive VP & CFO
Thank you very much for having us.
Mohit Bansal - Wells Fargo Securities, LLC, Research Division - Senior Equity Analyst
Thank you very much for joining. So I think we should start with -- I think a few years ago, you started with this -- when you joined as a CFO, so the Gilead 2.0 and oncology progress and everything. So we'll talk a lot about that. But before we get into that, let's just briefly touch upon the core business, the HIV business here. And we will get to the -- I think you want to spend a lot of time on oncology right?
Gilead Sciences Inc at Wells Fargo Healthcare Conference Transcript
Sep 06, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers